Full Press Release Details
Given notifies ICON that he will not seek a further term as Chairman of
DUBLIN--(BUSINESS WIRE)--November 29, 2012--ICON plc. (NASDAQ:ICLR)
(ISIN:IE0005711209), a global provider of outsourced development
services to the pharmaceutical, biotechnology and medical device
industries, today announced that Dr. Bruce Given, non-executive chairman
of the board, has notified the company that it is his intention not to
seek a second term as chairman when his current term expires on December
31st 2012. Dr. Given has served as ICON's chairman since 1st
January 2010 and has been a member of the company's board of directors
Dr. Given commented, "The time commitment for the
chairman's role was increasingly challenging given my operational
responsibilities outside of ICON. Having overseen a very successful
transition in the executive leadership of the company, new strategic
alliances, as well as a return to strong growth in revenues and
earnings, I believe the timing is right for me to relinquish the chair."
On behalf of the board, Mr. Ciaran Murray, ICON CEO, commented, "I
would like to thank Bruce for his leadership and support over the past
three years in his role as chairman."
The board of directors will now initiate a process to select a new
chairman, from among its members, to be appointed with effect from
The information contained in this release is as of 29th
November 2012. The statements made in this press release may contain
forward-looking statements that involve a number of risks and
uncertainties. A description of risks and uncertainties relating to ICON
and its business can be found in ICON's Annual Report for the fiscal
year ended December 31, 2011 and in the forms filed with the US
Securities and Exchange Commission, including the Forms 20-F, F-1, S-8
and F-3. ICON disclaims any intent or obligation to update these
forward-looking statements.
ICON plc is a global provider of outsourced development services to the
pharmaceutical, biotechnology and medical device industries. The company
specialises in the strategic development, management and analysis of
programs that support clinical development - from compound selection to
Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON
currently, operates from 82 locations in 40 countries and has
approximately 9,430 employees. Further information is available at www.iconplc.com.